(Q35114583)

6 August 2017

1 reference

title

Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies (English)

1 reference

6 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12714275

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00033-X

27 December 2023

author name string

Matthias Schott

1

1 reference

6 August 2017

Jochen Seissler

2

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12714275

27 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S104327600300033X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00033-X

https://api.elsevier.com/content/article/PII:S104327600300033X?httpAccept=text/plain

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00033-X

Trends in Endocrinology and Metabolism

27 December 2023

published in

1 reference

6 August 2017

volume

14

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

156-162

1 reference

The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Cross-presentation, dendritic cells, tolerance and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cells: multi-lineal and multi-functional

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Origin and differentiation of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cell regulation of TH1-TH2 development

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cell based tumor vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Response of human monocyte-derived dendritic cells to immunostimulatory DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Differentiation of T regulatory cells by immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Progress in human tumour immunology and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Follow-up evaluation of a phase II prostate cancer vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cell immuno-therapy in disseminated parathyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Control of hypercalcaemia of parathyroid carcinoma by immunisation.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Dendritic cell-based vaccination in solid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2803%2900033-X

7 January 2021

Clinical significance of defective dendritic cell differentiation in cancer

15

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00033-X

Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration

27 December 2023

34

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00033-X

Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine

27 December 2023

44

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00033-X

A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen

27 December 2023

61

1 reference

https://api.crossref.org/works/10.1016/S1043-2760(03)00033-X

27 December 2023

Identifiers

1 reference

6 August 2017

1 reference